Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nintedanib second-line study in differentiated or medullary thyroid cancer
2012-004295-19Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nintedanib in well-differentiated thyroid cancer (WDTC) and Medullary Thyroid Cancer (MTC) (2 cohorts), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Jun 2013; status: completed.
02
Drugs
nintedanib
03
Conditions
well-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2012-004295-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004295-19.